{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-010370","form_type":"8-K","ticker":"CBIO","cik":"0001253689","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2024-07-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.404822+00:00","generated_at":"2026-05-31T14:58:59.666751+00:00","sec_items":["2.05","5.02","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"GlycoMimetics cuts 80% workforce, begins strategic review after FDA setback for uproleselan","bullets":["FDA feedback requires an additional clinical trial for uproleselan in R/R AML; regulatory path uncertain.","Workforce reduced by 26 employees (~80%); expects $3.6M in severance charges in Q3 2024.","CMO Dr. Edwin Rock departs July 31; will receive 12 months' base salary severance and consulting deal.","Cash and equivalents ~$31.3M as of March 31; restructuring extends cash runway into Q2 2025.","Engaged Lucid Capital Markets to explore strategic alternatives including sale, merger, or licensing."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-010370","json":"https://secwatch.observer/filing/0001558370-24-010370.json","markdown":"https://secwatch.observer/filing/0001558370-24-010370.md","text":"https://secwatch.observer/filing/0001558370-24-010370.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1253689/000155837024010370/0001558370-24-010370-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1253689/000155837024010370/glyc-20240724x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T14:58:59.666751+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f6b3b07dab","claim":"Dr. Edwin Rock departed as Chief Medical Officer at CRESCENT BIOPHARMA, INC..","evidence_excerpt":"the employment of Dr. Edwin Rock, the Company’s Chief Medical Officer, will end on July 31, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837024010370/0001558370-24-010370-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"e6a05755c1c922c28abf7eb8cb9420016d729578","claim":"CRESCENT BIOPHARMA, INC. announced a restructuring with charges of approximately $3.6 million (reduction in the Company's workforce by 26 employees, or approximately 80% of its headcount).","evidence_excerpt":"in connection with the streamlined operating plan approved by the Board, on July 24, 2024, the authorized officers of the Company committed the Company to a corporate restructuring that includes a reduction in the Company's workforce by 26 employees, or approximately 80% of its headcount. The Company expects to substantially complete the reduction by July 31, 2024. The Company anticipates recognizing approximately $3.6 million in total charges in connection with the headcount reduction","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837024010370/0001558370-24-010370-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $3.6 million"},{"label":"Headcount","value":"reduction in the Company's workforce by 26 employees, or approximately 80% of its headcount"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}